1. Home
  2. NAMS vs NBHC Comparison

NAMS vs NBHC Comparison

Compare NAMS & NBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • NBHC
  • Stock Information
  • Founded
  • NAMS 2019
  • NBHC 2009
  • Country
  • NAMS Netherlands
  • NBHC United States
  • Employees
  • NAMS N/A
  • NBHC N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • NBHC Major Banks
  • Sector
  • NAMS Health Care
  • NBHC Finance
  • Exchange
  • NAMS Nasdaq
  • NBHC Nasdaq
  • Market Cap
  • NAMS 1.4B
  • NBHC 1.6B
  • IPO Year
  • NAMS N/A
  • NBHC 2012
  • Fundamental
  • Price
  • NAMS $19.03
  • NBHC $44.51
  • Analyst Decision
  • NAMS Strong Buy
  • NBHC Buy
  • Analyst Count
  • NAMS 6
  • NBHC 4
  • Target Price
  • NAMS $33.80
  • NBHC $45.50
  • AVG Volume (30 Days)
  • NAMS 243.4K
  • NBHC 169.8K
  • Earning Date
  • NAMS 01-01-0001
  • NBHC 10-22-2024
  • Dividend Yield
  • NAMS N/A
  • NBHC 2.53%
  • EPS Growth
  • NAMS N/A
  • NBHC 14.68
  • EPS
  • NAMS N/A
  • NBHC 3.31
  • Revenue
  • NAMS $7,424,000.00
  • NBHC $403,558,000.00
  • Revenue This Year
  • NAMS N/A
  • NBHC N/A
  • Revenue Next Year
  • NAMS N/A
  • NBHC $6.99
  • P/E Ratio
  • NAMS N/A
  • NBHC $13.46
  • Revenue Growth
  • NAMS N/A
  • NBHC 8.57
  • 52 Week Low
  • NAMS $5.63
  • NBHC $28.38
  • 52 Week High
  • NAMS $26.35
  • NBHC $46.52
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 69.87
  • NBHC 69.21
  • Support Level
  • NAMS $17.00
  • NBHC $40.27
  • Resistance Level
  • NAMS $19.41
  • NBHC $41.34
  • Average True Range (ATR)
  • NAMS 0.86
  • NBHC 0.91
  • MACD
  • NAMS 0.21
  • NBHC 0.38
  • Stochastic Oscillator
  • NAMS 90.26
  • NBHC 98.89

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About NBHC National Bank Holdings Corporation

National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit card, wire transfer, automated clearing house, and electronic bill payments.

Share on Social Networks: